<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743051</url>
  </required_header>
  <id_info>
    <org_study_id>ANAM-17-20</org_study_id>
    <secondary_id>2018-002926-22</secondary_id>
    <nct_id>NCT03743051</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate&#xD;
      the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC&#xD;
      with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once&#xD;
      daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at&#xD;
      least 1 hour before their first meal of the day&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Multicenter Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of clinically meaningful treatment benefit in weight</measure>
    <time_frame>From baseline until week 12</time_frame>
    <description>The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of clinically meaningful treatment benefit in 5-item Anorexia Symptom Subscale</measure>
    <time_frame>From baseline until week 12</time_frame>
    <description>The duration of treatment benefit is measured as the duration for which the patient observed a change from baseline superior or equal to the predefined threshold of clinical meaningfulness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>from baseline up to week 12</time_frame>
    <description>Mean change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 item Anorexia Symptom Subscale</measure>
    <time_frame>from baseline up to week 12</time_frame>
    <description>Mean change in 5 item Anorexia Symptom Subscale. The range of values is 0-20, and a higher score versus baseline means an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAACT total score</measure>
    <time_frame>from baseline up to week 12</time_frame>
    <description>Mean change in FAACT total score. FAACT (Functional Assessment of Anorexia/Cachexia Treatment) total score is obtained by summing the FACT-G (Functional Assessment Cancer Therapy- General Version) and the A/CS (anorexia/cachexia symptoms and concerns) domain; the range of values is 0-156, and a higher score versus baseline means an improvement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Composite Clinical Response (CCR)</measure>
    <time_frame>from baseline to week 9</time_frame>
    <description>CCR is a composite measure including both a ≥ 5% body weight gain from baseline and increase ≥ 2 points in the 5-item Anorexia Symptom Subscale score from baseline in patients who survive until the visits of the analysis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Cachexia; Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>100mg Anamorelin HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anamorelin Hydrochloride</intervention_name>
    <description>100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)</description>
    <arm_group_label>100mg Anamorelin HCl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo (administered as matching placebo tablets in the fasted condition)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Female or male ≥18 years of age&#xD;
&#xD;
          3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer&#xD;
             (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease&#xD;
&#xD;
          4. Body mass index &lt; 20 kg/m2 with involuntary weight loss of &gt;2% within 6 months prior&#xD;
             to screening&#xD;
&#xD;
          5. Ongoing problems with appetite/eating associated with the underlying cancer, as&#xD;
             determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤&#xD;
             37 points on the 12-item FAACT A/CS&#xD;
&#xD;
          6. Patient receiving or not receiving systemic anti-cancer treatment at the time of&#xD;
             screening are eligible to participate. Systemic anti-cancer treatment includes first,&#xD;
             second, third treatment line with chemotherapy/radiation therapy, immunotherapy or&#xD;
             targeted therapy.&#xD;
&#xD;
             Patient not receiving systemic anti-cancer treatment is eligible if:&#xD;
&#xD;
               1. Not planning to receive anti-cancer treatment and/or at least 14 days must be&#xD;
                  elapsed from the completion of prior treatment at the day of screening, in case&#xD;
                  underwent previous cycle OR&#xD;
&#xD;
               2. Planning to receive anti-cancer treatment within 14 days from randomization&#xD;
                  and/or at least 14 days must be elapsed from the completion of prior treatment at&#xD;
                  the day of screening, in case underwent previous cycle OR&#xD;
&#xD;
               3. Patient on palliative care treatment&#xD;
&#xD;
          7. ECOG performance status 0,1 or 2 at screening&#xD;
&#xD;
          8. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN or if hepatic metastases are present ≤ 5 x ULN&#xD;
&#xD;
          9. Adequate renal function, defined as creatinine ≤2 ULN, or calculated creatinine&#xD;
             clearance &gt;30 ml/minute&#xD;
&#xD;
         10. Female patient shall be: a) of non-childbearing potential or b) of childbearing&#xD;
             potential using reliable contraceptive measures and having a negative urine pregnancy&#xD;
             test within 24 hours prior to first dose of investigational product.&#xD;
&#xD;
             Notes:&#xD;
&#xD;
               1. Female patient of non-childbearing potential are defined as being in&#xD;
                  post-menopausal state since at least 1 year; or having documented surgical&#xD;
                  sterilization or hysterectomy at least 3 months before study participation.&#xD;
&#xD;
               2. Reliable contraceptive measures include implants, injectables, combined oral&#xD;
                  contraceptives, intrauterine devices, vasectomized partner or complete (long&#xD;
                  term) sexual abstinence.&#xD;
&#xD;
         11. The patient must be willing and able to comply with the protocol tests and procedures&#xD;
             All inclusion criteria will be checked at screening visit (Visit 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)&#xD;
&#xD;
          2. Woman who is pregnant or breast-feeding&#xD;
&#xD;
          3. Reversible causes of reduced food intake, as determined by the Investigator. These&#xD;
             causes may include but are not limited to:&#xD;
&#xD;
               1. NCI CTCAE Grade 3 or 4 oral mucositis,&#xD;
&#xD;
               2. NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and&#xD;
                  constipation],&#xD;
&#xD;
               3. mechanical obstructions making patient unable to eat, or&#xD;
&#xD;
               4. severe depression&#xD;
&#xD;
          4. Patient undergoing major surgery (central venous access placement and tumor biopsies&#xD;
             are not considered major surgery) within 4 weeks prior to randomization. Patient must&#xD;
             be well recovered from acute effects of surgery prior to screening. Patient should not&#xD;
             have plans to undergo major surgical procedures during the treatment period&#xD;
&#xD;
          5. Patient currently taking androgenic compounds (including but not limited to&#xD;
             testosterone, testosterone-like agents, oxandrolone, megestrol acetate,&#xD;
             corticosteroids, olanzapine, mirtazapine (however, long-term use of mirtazapine for&#xD;
             depression for at least four weeks prior to screening is allowed), dronabinol or&#xD;
             marijuana (cannabis) or any other prescription medication or off-label products&#xD;
             intended to increase appetite or treat unintentional weight loss&#xD;
&#xD;
          6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring&#xD;
             drainage, edema or evidence of ascites&#xD;
&#xD;
          7. Patient with uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
               1. History of myocardial infarction within the past 3 months&#xD;
&#xD;
               2. A-V block of second or third degree (may be eligible if currently have a&#xD;
                  pacemaker)&#xD;
&#xD;
               3. Unstable angina&#xD;
&#xD;
               4. Congestive heart failure within the past 3 months, if defined as NYHA class&#xD;
                  III-IV&#xD;
&#xD;
               5. Any history of clinically significant ventricular arrhythmias (such as&#xD;
                  ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW)&#xD;
                  syndrome, or torsade de pointes)&#xD;
&#xD;
               6. Uncontrolled hypertension (blood pressure &gt;150 mm Hg systolic and &gt;95 mm Hg&#xD;
                  diastolic)&#xD;
&#xD;
               7. Heart rate &lt; 50 beats per minute on pre-entry electrocardiogram and patient is&#xD;
                  symptomatic&#xD;
&#xD;
          8. Patient on drugs that may prolong the PR or QRS interval durations, such as any of the&#xD;
             antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)&#xD;
&#xD;
          9. Patient unable to readily swallow oral tablets&#xD;
&#xD;
         10. Patient with severe gastrointestinal disease (including esophagitis, gastritis,&#xD;
             malabsorption)&#xD;
&#xD;
         11. Patient with history of gastrectomy&#xD;
&#xD;
         12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus&#xD;
&#xD;
         13. Patient with cachexia caused by other reasons, as determined by the investigator such&#xD;
             as:&#xD;
&#xD;
               1. Severe COPD requiring use of home O2,&#xD;
&#xD;
               2. New York Heart Association (NYHA) class III-IV heart failure&#xD;
&#xD;
               3. AIDS&#xD;
&#xD;
               4. Uncontrolled thyroid disease&#xD;
&#xD;
         14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization&#xD;
&#xD;
         15. Patient currently receiving tube feedings or parenteral nutrition (either total or&#xD;
             partial).&#xD;
&#xD;
         16. Current excessive alcohol or illicit drug use&#xD;
&#xD;
         17. Any condition, including the presence of laboratory abnormalities, which in the&#xD;
             Investigator's opinion, places the subject at unacceptable risk if he/she were to&#xD;
             participate in the study or confounds the ability to interpret data from the study&#xD;
&#xD;
         18. Enrollment in a previous study with anamorelin HCl&#xD;
&#xD;
         19. Patient actively receiving a concurrent investigational agent, or having received an&#xD;
             investigational agent within 28 days of Day 1 All exclusion criteria will be checked&#xD;
             at screening visit (Visit 1).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edwin De Wit, MD</last_name>
    <phone>0041 919852161</phone>
    <email>edwin.dewit@helsinn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chen</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CARTI Cancer center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>the oncology Insitute of Hope and Innovation</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut</name>
      <address>
        <city>Plainville</city>
        <state>Connecticut</state>
        <zip>06062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>21st Century oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>mid Florida hematology and Oncology Center</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology hematology Associates, Ltd</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Goshen Center for Cancer Care</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MercyOne Waterloo Cancer Center</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Chmc F oundat1on</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Jackson oncology Associates, PLC</name>
      <address>
        <city>Jackson</city>
        <state>Minnesota</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>trinitas comprehensive cancer center/Trinitas Regional Medical Center</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Englewood Health</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialist</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Broome Oncology LLC</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>White Plains Hospital Center for Cancer Care</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialist</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Community Cancer Trial of Utah</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Complex Oncology Center - Burgas, Burgas</name>
      <address>
        <city>Burgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Multiprofile Hospital for Active Treatment- Dobrich, Dobrich</name>
      <address>
        <city>Dobrich</city>
        <zip>9300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Multiprofile Hospital for Acti ve T reatment ··Dr. Tota Venkova&quot; , Gabrovo</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology, Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda, Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology at Clinical hematology clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>clinic of medical oncology,hospital Sveta marina</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinic on Medical oncology University Muliprofile Hospital for active treatment &quot;Sveta Marina&quot;, Varna</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>K o ran y i National Institute of Pulmo nol ogy, 6th D epartm ent of Pulmono logy</name>
      <address>
        <city>Budapest</city>
        <zip>H-1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University o f D ebrecen C linical Center, Department of Pulmono log y</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Csongrad County Hospital of Chest Diseases, Department of Pulmonology</name>
      <address>
        <city>Deszk</city>
        <zip>H - 6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Veszprem C ounty Pulmonology I nstitute</name>
      <address>
        <city>Farkasgyepű</city>
        <zip>1-1-8582</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of the University of Pecs, Depaitment ofPulmonology</name>
      <address>
        <city>Pécs</city>
        <zip>H-7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fejer County St. Gyorgy University Teaching Hospital, Pulmonology Department I</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>H-8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jasz-N agy kun-Szo l nok County H eteny i G eza Hospital-Clinic, Department of Oncology</name>
      <address>
        <city>Szolnok</city>
        <zip>H-5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonology Institute Torokbalint</name>
      <address>
        <city>Törökbálint</city>
        <zip>H - 2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ferrara, Oncology department</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scientific Institute of Romagna for the study and treatment of cancer (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>Forli</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <state>Italia</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Versilia Hospital</name>
      <address>
        <city>Lido Di Camaiore</city>
        <state>Italia</state>
        <zip>55049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <state>Italia</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology reference center</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Healthcare Company of Monza (ASST Monza)</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU University Luigi Vanvitelli Oncoematology department</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Umberto I policlinico la Sapienza, Translational and Precision Medicine department</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Policlinic Fondation Agostino Gemelli</name>
      <address>
        <city>Rom</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Research Radiological Centre (Tsyb Medical Radiology Research Center)</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluga Region</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Usachev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evimed, LLC</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>lvanovo Regional Oncology Center</name>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primushko Republicun Clinical Oncology Center</name>
      <address>
        <city>Izhevsk</city>
        <zip>426009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Immanuel Kant Baltic Federal University</name>
      <address>
        <city>Kaliningrad</city>
        <zip>236016</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kursk Regiona l Clinical Oncology Center</name>
      <address>
        <city>Kursk</city>
        <zip>305524</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>YitaMed, LLC</name>
      <address>
        <city>Moscow</city>
        <zip>121 309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Headache Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Center</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Center</name>
      <address>
        <city>Omsk</city>
        <zip>644046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First I.P. Pavlov State Medical University of St. Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Outpatient Clinic #43</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tambov Regional Oncological Clinical Center</name>
      <address>
        <city>Tambov</city>
        <zip>392013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tomsk National Research Medical Center</name>
      <address>
        <city>Tomsk</city>
        <zip>634028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic of Pulmonology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center l\emnijsJca kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Military Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncomed-System, Specialized Hospital for Internal Diseases</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center K ragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

